Niagen Bioscience (NAGE) Share-based Compensation (2011 - 2026)

Niagen Bioscience (NAGE) has reported Share-based Compensation for 16 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 59.63% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $6.7 million (up 79.02% YoY), while the FY2025 annual figure was $6.1 million, up 65.95% from the prior year.
• Share-based Compensation declined to $1.7 million in Q1 2026 per NAGE's latest filing, from $1.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $1.9 million in Q1 2022 and bottomed at $735000.0 in Q3 2024.
• Historically, Share-based Compensation has averaged $1.3 million across 5 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2024 — Share-based Compensation slumped 34.2% — and 2025, when it soared 138.91%.
• Niagen Bioscience's Share-based Compensation stood at $1.3 million in 2022, then retreated by 21.79% to $1.0 million in 2023, then slipped by 27.48% to $752000.0 in 2024, then soared by 132.45% to $1.7 million in 2025, then decreased by 1.83% to $1.7 million in 2026.
• Business Quant data shows NAGE's Share-based Compensation at $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $1.8 million in Q3 2025.